Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Celgene Corp. agreed to a $74bn merger with Bristol-Myers Squibb Co.on Jan. 3, but it is maintaining its busy deal-making pace, unveiling a pair of similarly structured immuno-oncology (IO) partnerships Jan. 18 with Kyn Therapeutics and Obsidian Therapeutics Inc.
The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.
The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
The company hopes the drug will become the standard of care rescue treatment in asthma.
